Les métastases des cancers urothéliaux : place de la chimiothérapie

25 novembre 2008

Auteurs : T. Lebret, A. Méjean
Référence : Prog Urol, 2008, 18, S261, suppl. S7
   
 
 

 

 
Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser

   

 

 
 
 

Références

 

Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics 2008 CA Cancer J Clin 2008 ;  58 (2) : 71-96 [cross-ref]
 
Dinney C.P., McConkey D.J., Millikan R.E., et al. Focus on bladder cancer Cancer Cell 2004 ;  6 (2) : 111-116 [cross-ref]
 
Zerbib M., Bouchot O. Traitements des tumeurs infiltrantes de vessie. Rapport du congrès AFU 2002 Prog Urol 2002 ;  12 : 751-1178
 
Jakse G., Algaba F., Fossa S., Stenzl A., Sternberg C. Guidelines on bladder cancer: muscle-invasive and metastatic  European Association of Urology Guidelines Board EAU Guidelines Office The Netherlands: EAU (2007). 1-24.
 
Lebret T., Gaudez F., Hervé J., Barré M., Lugagne P.P., Botto M.H. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success Eur Urol 1998 ;  34 (1) : 67-72 [cross-ref]
 
Pan CX P.M Systemic therapy for advanced urothelial cancer: current status and future direction Genitourinary cancers symposium a multidisciplinary approach :  (2008).  57-58February 14-16.
 
Grosclaude P. Evolution de l’incidence et de la mortalité par cancer en France de 1978 à 2000, cancer de vessie. cancers/.
 
Irani J., Bernardini S., Bonnal J.L., Chauvet B., et al. Recommandations 2007 en onco-urologie: tumeurs urothéliales Prog Urol 2007 ;  17 (6) : 1065-1098 [cross-ref]
 
Botto H., Sebe P., Molinie V., Herve J.M., Yonneau L., Lebret T. Prostatic capsule and seminal-sparing cystectomy for bladder carcinoma: initial results for selected patients BJU Int 2004 ;  94 (7) : 1021-1025 [cross-ref]
 
Pectasides D., Pectasides M., Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review Eur Urol 2005 ;  48 (1) : 60-67 [cross-ref]
 
Neoadjuvant cisplatin, methotrexate, vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial International collaboration of trialists Lancet 1999 ;  354 (9178) : 533-540
 
Malkowicz S.B., van Poppel H., Mickisch G., et al. Muscle-invasive urothelial carcinoma of the bladder Urology 2007 ;  69 (Suppl 1) : 3-16 [inter-ref]
 
Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 0541, patients J Clin Oncol 2001 ;  19 (3) : 666-675 [cross-ref]
 
Madersbacher S., Hochreiter W., Burkhard F., Thalmann G.N., Danuser H., Markwalder R., Studer U.E. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy J Clin Oncol 2003 ;  21 (4) : 690-696 [cross-ref]
 
Ghoneim M.A., el-Mekresh M.M., el-Baz M.A., el-Attar I.A., Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases J Urol 1997 ;  158 (2) : 393-399 [cross-ref]
 
Shariat S.F., Karakiewicz P.I., Palapattu G.S., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium J Urol 2006 ;  176 (6Pt 1) : 2414-2422 [cross-ref]
 
Lebret T., Hervé J.M., Yonneau L., Barré P., Lugagne P.M., Butreau M., Molinié V., Botto H. Study of survival after cystectomy for bladder cancer. Report of 504 cases Prog Urol 2000 ;  10 (4) : 553-560
 
von der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., Moore M.J., Zimmermann A., Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 2005 ;  23 (21) : 4602-4608 [cross-ref]
 
Loehrer P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 1992 ;  10 (7) : 1066-1073 [cross-ref]
 
Ruggeri E.M., Giannarelli D., Bria E., Carlini P., Felici A., Nelli F., Gallucci M., Cognetti F., Pollera C.F. Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies Cancer 2006 ;  106 (4) : 783-788 [cross-ref]
 
Siefker-Radtke A.O., Millikan R.E., Tu S.M., Moore D.F., Smith T.L., Williams D., Logothetis C.J. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer J Clin Oncol 2002 ;  20 (5) : 1361-1367 [cross-ref]
 
Bajorin D.F., Dodd P.M., Mazumdar M., Fazzari M., McCaffrey J.A., Scher H.I., Herr H., Higgins G., Boyle M.G. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy J Clin Oncol 1999 ;  17 (10) : 3173-3181 [cross-ref]
 
Sternberg C.N. Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role? Ann Oncol 2002 ;  13 (Suppl 4) : 273-279 [cross-ref]
 
de Braud F., Maffezzini M., Vitale V., Bruzzi P., Gatta G., Hendry W.F., Sternberg C.N. Bladder cancer Crit Rev Oncol Hematol 2002 ;  41 (1) : 89-106 [cross-ref]
 
Logothetis C.J., Dexeus F.H., Finn L., Sella A., Amato R.J., Ayala A.G., Kilbourn R.G. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors J Clin Oncol 1990 ;  8 (6) : 1050-1055 [cross-ref]
 
Sternberg C.N., Yagoda A., Scher H.I., et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium J Urol 1985 ;  133 (3) : 403-407 [cross-ref]
 
Harker W.G., Meyers F.J., Freiha F.S., Palmer J.M., Shortliffe L.D., Hannigan J.F., McWhirter K.M., Torti F.M. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study J Clin Oncol 1985 ;  3 (11) : 1463-1470 [cross-ref]
 
Bamias A., Tikiakos I., Karali M.D., Dimopoulos M.A. Systemic chemotherapy in inoperable or metastatic bladder cancer Ann Oncol 2006 ;  17 (4) : 553-561 [cross-ref]
 
Rosenberg J.E., Cerroll P.R., Small E.J. Update on chemotherapy for advanced bladder cancer J Urol 2005 ;  174 (1) : 14-20 [cross-ref]
 
Garcia J.A., Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies J Clin Oncol 2006 ;  24 (35) : 5545-5551 [cross-ref]
 
Sternberg C.N., Donat S.M., Bellmunt J., et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer Urology 2007 ;  69 (1Suppl) : 62-79 [inter-ref]
 
Radhavan D. Biology and management of bladder cancer N Engl J Med 1990 ;  322 : 1129-1138
 
Yagoda A., Watson R.C., Whitmore W.F., Grabstald H., Middleman M.P., Krakoff I.H. Adriamycin in advanced urinary tract cancer: experience in 42 patients and review of the literature Cancer 1977 ;  39 (1) : 279-285 [cross-ref]
 
Natale R.B., Yagoda A., Watson R.C., Whitmore W.F., Blumenreich M., Braun D.W. Methotrexate: an active drug in bladder cancer Cancer 1981 ;  47 (6) : 1246-1250 [cross-ref]
 
Blumenreich M.S., Yagoda A., Natale R.B., Watson R.C. Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors Cancer 1982 ;  50 (3) : 435-438 [cross-ref]
 
Blumenreich M.S., Needles B., Yagoda A., Sogani P., Grabstald H., Whitmore W.F. Intravesical cisplatin for superficial bladder tumors Cancer 1982 ;  50 (5) : 863-865 [cross-ref]
 
Yagoda A. Phase-II trials in patients with urothelial tract tumors Memorial Sloan-Kettering Cancer Center Cancer Chemother Pharmacol 1983 ;  11 : S9-12
 
Sternberg C.N., Yagoda A., Scher H.I., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse Cancer 1989 ;  64 (12) : 2448-2458 [cross-ref]
 
Saxman S.B., Propert K.J., Einhorn L.H., Crawford E.D., Tannock I., Raghavan D., Loehrer P.J., Trump D. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 1997 ;  15 (7) : 2564-2569 [cross-ref]
 
Geller N.L., Sternberg C.N., Penenberg D., Scher H., Yagoda A. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy Cancer 1991 ;  67 (6) : 1525-1531 [cross-ref]
 
Dodd P.M., McCaffrey J.A., Herr H., Mazumdar M., Bacik J., Higgins G., Boyle M.G., Scher H.I., Bajorin D.F. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma J Clin Oncol 1999 ;  17 (8) : 2546-2552
 
Roth B.J., Bajorin D.F. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world J Urol 1995 ;  153 (3Pt2) : 894-900 [cross-ref]
 
Igawa M., Ohkuchi T., Ueki T., Ueda M., Okada K., Usui T. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer J Urol 1990 ;  144 (3) : 662-665 [cross-ref]
 
Iaffaioli R.V., Milano A., Caponigro F. Therapy of metastatic bladder carcinoma Ann Oncol 2007 ;  18 (Suppl 6) : vi153-6.
 
Hillcoat B.L., Raghavan D., Matthews J., et al. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract J Clin Oncol 1989 ;  7 (6) : 706-709 [cross-ref]
 
Stoter G., Splinter T.A., Child J.A., Fosså S.D., Denis L., van Oosterom A.T., de Pauw M., Sylvester R. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder J Urol 1987 ;  137 (4) : 663-667 [cross-ref]
 
Mead G.M., Russell M., Clark P., Harland S.J., Harper P.G., Cowan R., Roberts J.T., Uscinska B.M., Griffiths G.O., Parmar M.K. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party Br J Cancer 1998 ;  78 (8) : 1067-1075 [cross-ref]
 
von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 2000 ;  18 (17) : 3068-3077 [cross-ref]
 
Dreicer R., Manola J., Roth B.J., See W.A., Kuross S., Edelman M.J., Hudes G.R., Wilding G. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium Cancer 2004 ;  100 (8) : 1639-1645 [cross-ref]
 
Bamias A., Aravantinos G., Deliveliotis C., et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group J Clin Oncol 2004 ;  22 (2) : 220-228 [cross-ref]
 
Sternberg C.N., de Mulder P.H., Schornagel J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no 30924 J Clin Oncol 2001 ;  19 (10) : 2638-2646 [cross-ref]
 
Sengelov L., Kamby C., von der Maase H. Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years Eur Urol 2001 ;  39 : 634-642 [cross-ref]
 
Juffs H.G., Moore M.J., Tannock I.F. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer Lancet Oncol 2002 ;  3 : 738-747 [inter-ref]
 
Von-der-Maase H. Current and future perspectives in advanced bladder cancer: is there a new standard? Sem Oncol 2002 ;  29 : 3-14 [cross-ref]
 
Bamias A., Tiliakos I., Karali M.D., Dimopoulos M.A. Systemic chemotherapy in inoperable or metastatic bladder cancer Ann Oncol 2006 ;  17 (4) : 553-561 [cross-ref]
 
Gabrilove J.L., Jakubowski A., Fain K., et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium J Clin Invest 1988 ;  82 (4) : 1454-1461 [cross-ref]
 
Loehrer P.J., Elson P., Dreicer R., Hahn R., Nichols C.R., Williams R., Einhorn L.H. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial J Clin Oncol 1994 ;  12 (3) : 483-488 [cross-ref]
 
Logothetis C.J., Finn L.D., Smith T., Kilbourn R.G., Ellerhorst J.A., Zukiwski A.A., Sella A., Tu S.M., Amato R.J. Escalated MVAC with or without recombinant human granulocyte-macrophage colonystimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial J Clin Oncol 1995 ;  13 (9) : 2272-2277 [cross-ref]
 
Jakubowski A.A., Souza L., Kelly F., Fain K., Budman D., Clarkson B., Bonilla M.A., Moore M.A., Gabrilove J. Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia N Engl J Med 1989 ;  320 (1) : 38-42 [cross-ref]
 
Sternberg C.N., de Mulder P., Schornagel J.H., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours Eur J Cancer 2006 ;  42 (1) : 50-54 [cross-ref]
 
Calabro F., Sternberg C.N. New drugs and new approaches for the treatment of metastatic urothelial cancer World J Urol 2002 ;  20 : 158-166
 
Calabro F., Sternberg C.N. High-risk metastatic urothelial cancer: chances for cure? Curr Opin Urol 2002 ;  12 : 441-448 [cross-ref]
 
Bellmunt J., Albanell J., Gallego O.S., Ribas A., Vicente P., Carulla J., De Torres J., Morote J., Lopez M., Solé L.A. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy Cancer 1992 ;  70 (7) : 1974-1979 [cross-ref]
 
Waxman J., Barton C. Carboplatin-based chemotherapy for bladder cancer Cancer Treat Rev 1993 ;  19 (suppl C) : 21-25 [cross-ref]
 
Vogelzang N.J. Future directions for gemcitabine in the treatment of genitourinary cancer Semin Oncol 2002 ;  29 (suppl3) : 40-45 [cross-ref]
 
Sternberg C.N. Gemcitabine in bladder cancer Semin Oncol 2000 ;  27 : 31-39
 
von der Maase H. Gemcitabine in transitional cell carcinoma of the urothe Expert Rev Anticancer Ther 2003 ;  3 : 11-19 [cross-ref]
 
Pollera C.F., Ceribelli A., Crecco M., Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a Phase 1 study Ann Oncol 1994 ;  5 (2) : 182-184 [cross-ref]
 
Dreicer R., Gustin D.M., See W.A., Williams R.D. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy J Urol 1996 ;  156 (5) : 1606-1608 [cross-ref]
 
Roth B.J., Dreicer R., Einhorn L.H. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group J Clin Oncol 1994 ;  12 : 2264-2270 [cross-ref]
 
Murphy B.A., Johnson D.R., Smith J., el al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer Proceedings of the American Society of Clinical Oncology :  (1996).  May 18-21. Abstract 617.
 
Burch P.A., Richardson R.L., Cha S.S., Sargent D.J., Pitot H.C., Kaur J.S., Camoriano J.K. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer J Urol 2000 Nov ;  164 (5) : 1538-1542 [cross-ref]
 
de Wit R., Kruit W.H., Stoter G., de Boer M., Kerger J., Verweij J. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients Br J Cancer 1998 ;  78 (10) : 1342-1345 [cross-ref]
 
McCaffrey J.A., Hilton S., Mazumdar M., Sadan S., Kelly W.K., Scher H.I., Bajorin D.F. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma J Clin Oncol 1997 ;  15 (5) : 1853-1857 [cross-ref]
 
Sengeløv L., Kamby C., Lund B., Engelholm S.A. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study J Clin Oncol 1998 ;  16 (10) : 3392-3397
 
Garcia del Muro X., Marcuello E., Gumá J., Paz-Ares L., Climent M.A., Carles J., Parra M.S., Tisaire J.L., Maroto P., Germá J.R. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer Br J Cancer 2002 ;  86 (3) : 326-330
 
Dimopoulos M.A., Bakoyannis C., Georgoulias V., et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group Ann Oncol 1999 ;  10 (11) : 1385-1388 [cross-ref]
 
Bajorin D.F., McCaffrey J.A., Dodd P.M., Hilton S., Mazumdar M., Kelly W.K., Herr H., Scher H.I., Icasiano E., Higgins G. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules Cancer 2000 ;  88 (7) : 1671-1678 [cross-ref]
 
Millikan R.E., Plunkett W.K., Smith T.L., Williams D.L., Logothetis C.J. Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin Cancer 2001 ;  92 (1) : 194-199 [cross-ref]
 
Plunkett W.W., Ghandi V. Nucleoside analogs: cellular pharmacology. Mechanisms of action and strategies for combination therapy Nudeoside Analogs in Cancer Therapy USA: Marcel Dekker. Inc. NY (1997).  1-35
 
Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates Invest New Drugs 2006 ;  24 (1) : 37-77 [cross-ref]
 
Paz-Ares L., Bezares S., Tabernero J.M., Castellanos D. Cortes-Funes H. Review of a promising new agent--pemetrexed disodium Cancer 2003 ;  97 (8Suppl) : 2056-2063 [cross-ref]
 
Misset J.L. Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer Semin Oncol 2002 ;  29 (supp13) : 36-39 [cross-ref]
 
Sweeney C.J., Roth B.J., Kabbinavar F.F., Vaughn D.J., Arning M., Curiel R.E., Obasaju C.K., Wang Y., Nicol S.J., Kaufman D.S. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium J Clin Oncol 2006 ;  24 (21) : 3451-3457 [cross-ref]
 
Von der Maase H., Lehmann J., Gravis G., Joensuu H., Geertsen P.F., Gough J., Chen G., Kania M. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium Ann Oncol 2006 ;  17 (10) : 1533-1538 [cross-ref]
 
Stadler W.M., Kuzel T., Roth B., Raghavan D., Dorr F.A. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer J Clin Oncol 1997 ;  15 (11) : 3394-3398 [cross-ref]
 
von der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., Moore M.J., Zimmermann A., Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 2005 ;  23 (21) : 4602-4608 [cross-ref]
 
von der Maase H., Andersen L., Crinò L., Weinknecht S., Dogliotti L. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial Ann Oncol 1999 ;  10 (12) : 1461-1465 [cross-ref]
 
Kaufman D., Raghavan D., Carducci M., Levine E.G., Murphy B., Aisner J., Kuzel T., Nicol S., Oh W., Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer J Clin Oncol 2000 ;  18 (9) : 1921-1927 [cross-ref]
 
Moore M.J., Winquist E.W., Murray N., Tannock I.F., Huan S., Bennett K., Walsh W., Seymour L. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 1999 ;  17 (9) : 2876-2881
 
Stadler W.M., Hayden A., von der Maase H., Roychowdhury D., Dogliotti L., Seymour L., Kaufmann D., Moore M. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer Urol Oncol 2002 ;  7 (4) : 153-157 [cross-ref]
 
Sternberg C.N., Calabrò F., Pizzocaro G., Marini L., Schnetzer S., Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy Cancer 2001 ;  92 (12) : 2993-2998 [cross-ref]
 
Rixe O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel Biochem Pharmacol 1996 ;  52 (12) : 1855-1865 [cross-ref]
 
Culine S., Rebillard X., Iborra F., Mottet N., Faix A., Ayuso D., Pinguet F. Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study Anticancer Res 2003 ;  23 (2C) : 1903-1906
 
Theodore C., Bidault F., Bouvet-Forteau N., Abdelatif M., Fizazi K., di Palma M., Wibault P., de Crevoisier R., Laplanche A. A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract Ann Oncol 2006 ;  17 (6) : 990-994 [cross-ref]
 
Carles J., Esteban E., Climent M., Font A., Gonzalez-Larriba J.L., Berrocal A., Garcia-Ribas I., Marfa X., Fabregat X., Albanell J., Bellmunt J.Spanish Oncology Genito Urinary Group Study Group Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer Ann Oncol 2007 ;  18 (8) : 1359-1362 [cross-ref]
 
Meluch A.A., Greco F.A., Burris H.A., O’Rourke T., Ortega G., Steis R.G., Morrissey L.H., Johnson V., Hainsworth J.D. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network J Clin Oncol 2001 ;  19 (12) : 3018-3024 [cross-ref]
 
Li J., Juliar B., Yiannoutsos C., Ansari R., Fox E., Fisch M.J., Einhorn L.H., Sweeney C.J. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study J Clin Oncol 2005 ;  23 (6) : 1185-1191 [cross-ref]
 
Srinivas S., Guardino A.E. A nonplatinum combination in metastatic transitional cell carcinoma Am J Clin Oncol 2005 ;  28 (2) : 114-118 [cross-ref]
 
Fechner G., Siener R., Reimann M., Kobalz L., Albers P.German Association Of Urologic Oncology (Auo) Bladder Cancer Study Group Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99) Int J Clin Pract 2006 ;  60 (1) : 27-31 [cross-ref]
 
Kaufman D.S., Carducci M.A., Kuzel T.M., Todd M.B., Oh W.K., Smith M.R., Ye Z., Nicol S.J., Stadler W.M. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer Urol Oncol 2004 ;  22 (5) : 393-397 [cross-ref]
 
Dreicer R., Manola J., Schneider D.J., Schwerkoske J.F., George C.S., Roth B.J., Wilding G.Eastern Cooperative Oncology Group. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group Cancer 2003 ;  97 (11) : 2743-2747 [cross-ref]
 
Small E.J., Lew D., Redman B.G., Petrylak D.P., Hammond N., Gross H.M., Eastham J.A., Crawford E.d Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitionalcell carcinoma: the importance of survival as a clinical trial end point J Clin Oncol 2000 ;  18 (13) : 2537-2544 [cross-ref]
 
Dreicer R., Manola J., Roth B.J., See W.A., Kuross S., Edelman M.J., Hudes G.R., Wilding G. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium Cancer 2004 ;  100 (8) : 1639-1645 [cross-ref]
 
Vaughn D.J., Malkowicz S.B., Zoltick B., Mick R., Ramchandani P., Holroyde C., Armstead B., Fox K., Wein A. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen J Clin Oncol 1998 ;  16 (1) : 255-260 [cross-ref]
 
Redman B.G., Smith D.C., Flaherty L., Du W., Hussain M. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma J Clin Oncol 1998 ;  16 (5) : 1844-1848 [cross-ref]
 
Bellmunt J., Ribas A., Eres N., Albanell J., Almanza C., Bermejo B., Solé L.A., Baselga J. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma Cancer 1997 ;  80 (10) : 1966-1972 [cross-ref]
 
Logothetis C.J., Hossan E., Recondo G., Sella A., Ellerhorst J., Kilbourn R., Zukiwski A. Amato R 5-Fluorouracil and interferonalpha in chemotherapy refractory bladder carcinoma: an effective regimen Anticancer Res 1994 ;  14 (3B) : 1265-1269
 
Siefker-Radtke A.O., Millikan R.E., Tu S.M., Moore D.F., Smith T.L., Williams D., Logothetis C.J. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer J Clin Oncol 2002 ;  20 (5) : 1361-1367 [cross-ref]
 
Hussain M., Vaishampayan U., Smith D.C. Novel gemcitabinecontaining triplets in the management of urothelial cancer Semin Oncol 2002 ;  29 (1Suppl 3) : 20-24 [cross-ref]
 
Bellmunt J., Guillem V., Paz-Ares L., et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group J Clin Oncol 2000 ;  18 (18) : 3247-3255 [cross-ref]
 
Hussain M., Vaishampayan U., Du W., Redman B., Smith D.C. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer J Clin Oncol 2001 ;  19 (9) : 2527-2533 [cross-ref]
 
Bajorin D.F., McCaffrey J.A., Dodd P.M., Hilton S., Mazumdar M., Kelly W.K., Herr H., Scher H.I., Icasiano E., Higgins G. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules Cancer 2000 ;  88 (7) : 1671-1678 [cross-ref]
 
Dodd P.M., McCaffrey J.A., Hilton S., Mazumdar M., Herr H., Kelly W.K., Icasiano E., Boyle M.G., Bajorin D.F. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract J Clin Oncol 2000 ;  18 (4) : 840-846
 
Bellmunt J, Albiol S, Suárez C, Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol 2008:in press.
 
Pollera C.F., Nelli F. Developing innovative strategies for advanced transitional cell carcinoma of the bladder Expert Rev Anticancer Ther 2006 ;  6 (1) : 83-92 [cross-ref]
 
Bellmunt J., de Wit R., Albanell J., Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in “unfit” patients with advanced bladder cancer Eur J Cancer 2001 ;  37 (17) : 2212-2215 [cross-ref]
 
Carles J., Nogué M., Domènech M., Pérez C., Saigí E., Villadiego K., Guasch I., Ibeas R. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function Oncology 2000 ;  59 (1) : 24-27 [cross-ref]
 
Gitlitz B.J., Baker C., Chapman Y., Allen H.J., Bosserman L.D., Patel R., Sanchez J.D., Shapiro R.M., Figlin R.A. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma Cancer 2003 ;  98 (9) : 1863-1869 [cross-ref]
 
Bamias A., Aravantinos G., Deliveliotis C., et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group J Clin Oncol 2004 ;  22 (2) : 220-228 [cross-ref]
 
Pagliaro L.C., Millikan R.E., Tu S.M., Williams D., Daliani D., Papandreou C.N., Logothetis C.J. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma J Clin Oncol 2002 ;  20 (13) : 2965-2970 [cross-ref]
 
Vaughn D.J., Broome C.M., Hussain M., Gutheil J.C., Markowitz A.B. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer J Clin Oncol 2002 ;  20 (4) : 937-940 [cross-ref]
 
Krege S., Rembrink V., Börgermann C., Otto T., Rübben H. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study J Urol 2001 ;  165 (1) : 67-71 [cross-ref]
 
Sweeney C.J., Roth B.J., Kabbinavar F.F., Vaughn D.J., Arning M., Curiel R.E., Obasaju C.K., Wang Y., Nicol S.J., Kaufman D.S. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium J Clin Oncol 2006 ;  24 (21) : 3451-3457 [cross-ref]
 
Galsky M.D., Mironov S., Iasonos A., Scattergood J., Boyle M.G., Bajorin D.F. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma Invest New Drugs 2007 ;  25 (3) : 265-270 [cross-ref]
 
Culine S., Theodore C., De Santis M., Bui B., Demkow T., Lorenz J., Rolland F., Delgado F.M., Longerey B., James N. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen Br J Cancer 2006 ;  94 (10) : 1395-1401 [cross-ref]
 
Vaughn DJ, Srinivas S, Petrylak P. Vinflunine (VFL) in patients with platinum-refractoty transitional cell carcinoma of the urothelium (TCCU): results of a large phase II study. Genitourinary cancer symposium, ASCO-GU, February 14-16, San Francisco, abstract 316, p 250.
 
Lin C.C., Hsu C.H., Huang C.Y. Gemcitabine and ifosfamide as a second line treatment for cis-platin-refractory metastatic urothelial carcinoma: a phase II study Anti-Cancer Drugs 2007 ;  18 : 487-491 [cross-ref]
 
Cheng L., Pan C.X., Yang X.J., et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients Cancer 2004 ;  101 (5) : 957-962 [cross-ref]
 
Grignon D.J., Ro J.Y., Ayala A.G., Shum D.T., Ordóñez N.G., Logothetis C.J., Johnson D.E., Mackay B. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases Cancer 1992 ;  69 (2) : 527-536 [cross-ref]
 
Oesterling J.E., Brendler C.B., Burgers J.K., Marshall F.F., Epstein J.I. Advanced small cell carcinoma of the bladder. Successful treatment with combined radical cystoprostatectomy and adjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy Cancer 1990 May 1 ;  65 (9) : 1928-1936 [cross-ref]
 
Quek M.L., Nichols P.W., Yamzon J., Daneshmand S., Miranda G., Cai J., Groshen S., Stein J.P., Skinner D.G. Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience J Urol 2005 ;  174 (1) : 93-96 [cross-ref]
 
Siefker-Radtke A.O., Dinney C.P., Abrahams N.A., Moran C., Shen Y., Pisters L.L., Grossman H.B., Swanson D.A., Millikan R.E. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D Anderson cancer experience J Urol 2004 ;  172 (2) : 481-484 [cross-ref]
 
Bex A., Nieuwenhuijzen J.A., Kerst M., Pos F., van Boven H., Meinhardt W., Horenblas S. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer Urology 2005 ;  65 (2) : 295-299 [inter-ref]
 
Black PC, Brown GA, Dinney CP. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 2008:in press.
 
Henly D.R., Farrow G.M., Zincke H. Urachal cancer: role of conservative surgery Urology 1993 ;  42 (6) : 635-639 [cross-ref]
 
Siefker-Radtke A.O., Gee J., Shen Y., Wen S., Daliani D., Millikan R.E., Pisters L.L. Multimodality management of urachal carcinoma: the M D. Anderson Cancer Center experience J Urol 2003 ;  169 (4) : 1295-1298 [cross-ref]
 
Siefker-Radtke A. Urachal carcinoma: surgical and chemotherapeutic options Expert Rev Anticancer Ther 2006 ;  6 (12) : 1715-1721 [cross-ref]
 
Nevin J.E., Melnick I., Baggerly J.T., Easley C.A., Landes R. Advanced carcinoma of bladder: treatment using hypogastric artery infusion with 5-fluorouracil, either as a single agent or in combination with bleomycin or adriamycin and supervoltage radiation J Urol 1974 ;  112 (6) : 752-758 [cross-ref]
 
Logothetis C.J., Samuels M.L., Ogden S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C Urology 1985 ;  26 (3) : 252-255 [cross-ref]
 
Ghoneim M.A., Ashamalla A., Gaballa M.A., Ibrahim E.I. Cystectomy for carcinoma of the bilharzial bladder. 126 patients 10 years later Br J Urol 1985 ;  57 (3) : 303-350
 
Ghoneim M.A., Abdel-Latif M., el-Mekresh M., Abol-Enein H., Mosbah A., Ashamallah A., el-Baz M.A. Radical cystectomy for carcinoma of the bladder: 2 720 consecutive cases 5 years later J Urol 2008 ;  180 (1) : 121-127 [cross-ref]
 
Khaled H.M., Gad el-Mawla N., el-Said A., Hamza M.R., Gaafar R., el-Attar I., Abu Rabia A., Magrath I. Combination chemotherapy for advanced bilharzial bladder carcinoma Ann Oncol 1996 ;  7 (7) : 751-754 [cross-ref]
 
Logothetis C.J., Johnson D.E., Chong C., et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update J Clin Oncol 1988 ;  6 (10) : 1590-1596 [cross-ref]
 
Zawan H., Moharan H., Fouda A., Kamem Y.M. Effective and safe as a single agent treatment of locally advanced or metastatic bilharzial-related bladeer cancer Proc Am Soc Clin Oncol 2002 ;  21 : 2410abst.
 
Khaled H.M. Systemic management of bladder cancer in Egypt: revisited J Egypt Natl Canc Inst 2005 ;  17 (3) : 127-131
 
Wright J.L., Black P.C., Brown G.A., Porter M.P., Kamat A.M., Dinney C.P., Lin D.W. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder J Urol 2007 ;  178 (6) : 2302-2306
 
Damiano R., D’Armiento M., Cantiello F., Amorosi A., Tagliaferri P., Sacco R., Venuta S. Gemcitabine and cisplatin following surgical treatment of urinary bladder carcinosarcoma Tumori 2004 ;  90 (5) : 458-460
 
Froehner M., Gaertner H.J., Manseck A., Wirth M.P. Durable complete remission of metastatic sarcomatoid carcinoma of the bladder with cisplatin and gemcitabine in an 80-year-old man Urology 2001 ;  58 (5) : 799 [inter-ref]
 
Lopez-Beltran A., Pacelli A., Rothenberg H.J., Wollan P.C., Zincke H., Blute M.L., Bostwick D.G. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases J Urol 1998 ;  159 (5) : 1497-1503 [cross-ref]
 
Yoshida S., Nakagomi K., Goto S., Kobayashi S. Malignant pheochromocytoma of the urinary bladder: effectiveness of radiotherapy in conjunction with chemotherapy Int J Urol 2004 ;  11 (3) : 175-177 [cross-ref]
 
Ali-el-Dein B., el-Sobky E., el-Baz M., Shaaban A.A. Abdominal and pelvic extra-adrenal paraganglioma: a review of literature and a report on 7 cases In Vivo 2002 ;  16 (4) : 249-254
 
Piédrola G., López E., Rueda M.D., López R., Serrano J., Sancho M. Malignant pheochromocytoma of the bladder: current controversies Eur Urol 1997 ;  31 (1) : 122-125
 
   
 
 
   

 

© 2008  Elsevier Masson SAS. Tous droits réservés.